Atrium Therapeutics, Inc. (RNA)

NASDAQ: RNA · Real-Time Price · USD

12.77

-0.22 (-1.69%)

At close: Apr 30, 2026, 4:00 PM EDT

12.96

+0.19 (1.49%)

After-hours: Apr 30, 2026, 4:16 PM EDT

Atrium Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Net Income	-49.5	-25.12	-6.39
Depreciation & Amortization	0.32	0.17	0.14
Loss (Gain) From Sale of Assets	0.14	-	-
Stock-Based Compensation	7.68	3.18	2.51
Other Operating Activities	0.43	12.11	0.2
Change in Accounts Receivable	-	0.75	1.39
Change in Accounts Payable	3.73	0.03	-0.05
Change in Unearned Revenue	-8.62	-10.11	62.78
Change in Other Net Operating Assets	4.69	-3.56	-4.19
Operating Cash Flow	-41.13	-22.55	56.39
Capital Expenditures	-1.45	-0.27	-0.32
Investing Cash Flow	-1.45	-0.27	-0.32
Other Financing Activities	42.57	22.82	-56.07
Financing Cash Flow	42.57	22.82	-56.07
Free Cash Flow	-42.57	-22.82	56.07
Free Cash Flow Margin	-228.67%	-209.41%	574.25%
Free Cash Flow Per Share	-2.74	-	-
Levered Free Cash Flow	-11.65	-12.01	-
Unlevered Free Cash Flow	-11.65	-12.01	-
Change in Working Capital	-0.2	-12.89	59.94

Source: S&P Global Market Intelligence. Standard template. Financial Sources.